AgeX Therapeutics, Inc. (AGE)

EBITDA Growth

-291.02%

TTM · Period ending:

AGE logo

AGE EBITDA Growth

Year-over-year change vs the same period a year earlier

Latest reported-291.02%
AGE TTM EBITDA YoY % (-9.25% → -291.02%)
High-resolution chart · PNG

AGE ebitda growth history

Trailing twelve months (TTM). Each value covers four complete reported quarters.

AgeX Therapeutics, Inc. EBITDA Growth — Trailing twelve months (TTM)
Period endingEBITDA Growth
-291.024%
-246.3321%
-877.5464%
127.0414%
147.8673%
168.3735%
122.5247%
-107.7514%
-165.0359%
-141.6385%
-39.0078%
-13.1726%
0.7952%
8.2171%
27.8925%
28.5224%
31.7652%
29.4539%
-1.625%
0.3538%
2.4142%
6.186%
18.8575%
21.7327%
5.3895%
-12.4087%
-9.2541%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.